CANF (Can Fite Biopharma) Float Percentage Of Total Shares Outstanding: 99.56% (As of Jun. 27, 2026)


CANF Can Fite Biopharma Ltd CANF
55 GF Score
Price $2.75
GF Value $5.68
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Float Percentage Of Total Shares Outstanding?

Can Fite Biopharma CANF -6.46% 55 Float Percentage Of Total Shares Outstanding is 99.56% as of Jun. 27, 2026. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.68 (Possible Value Trap). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Can Fite Biopharma's float shares is 2.13 Mil. Can Fite Biopharma's total shares outstanding is 2.14 Mil. Can Fite Biopharma's float percentage of total shares outstanding is 99.56%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Can Fite Biopharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Can Fite Biopharma's Institutional Ownership is 6.45%.

CANF
55GF Score
Can Fite Biopharma Ltd CANF
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Can Fite Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Can Fite Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2.13/2.14
=99.56%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.56% mean?
Can Fite Biopharma (CANF) has a Float Percentage Of Total Shares Outstanding of 99.56% as of Jun. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Can Fite Biopharma and its competitors.
Is Can Fite Biopharma's Float Percentage Of Total Shares Outstanding too high?
Can Fite Biopharma's current Float Percentage Of Total Shares Outstanding is 99.56%. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Can Fite Biopharma's Float Percentage Of Total Shares Outstanding of 99.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current Float Percentage Of Total Shares Outstanding is 99.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.68, compared to a current price of $2.75 — trading 51.6% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.56%. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Float Percentage Of Total Shares Outstanding is 99.56% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $2.75 is trading 51.6% below its estimated GF Value™ of $5.68. GuruFocus considers Can Fite Biopharma to be Possible Value Trap.

Key valuation signals for CANF:

  • Float Percentage Of Total Shares Outstanding: 99.56%
  • GF Value™: $5.68 vs. price of $2.75 (51.6% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score

Get the complete analysis for CANF

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price
$5.68
GF Value